market folly

Bill Ackman's hedge fund firm Pershing Square Capital has filed a 13D with the SEC regarding its position in Zoetis (ZTS).  Previously, we highlighted that Pershing was offering ZTS shares for sale.  Now, we get a sense as to how much of their position they've offloaded.

The 13D indicates Pershing now owns 3.8% of the company with 18.89 million shares.  This means they've sold 22.93 million ZTS shares since the end of the first quarter.

They were out selling Zoetis shares throughout June and into early July at prices $45.57 and $48.18.  ZTS currently trades around $48.47.

We've also highlighted some other recent Pershing Square portfolio moves.

Per Google Finance, Zoetis is "in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties. It also offers other product categories, such as nutritionals and agribusiness."